We further examined the expression array data of tumor biopsies from the patients that achieved a pCR after neoadjuvant taxane-based therapy and those with residual disease (non-pCR), we showed a downregulated expression of TUBB, TUBB3 and TUBB6 genes in the tumors from the patients with residual disease to taxane–based therapy compared to those with pCR. This evidence concerns the gene TUBB6 and neoplasm.